Timeline
A chronological record of the Treatment of Lead-Exposed Children trial — from the regulatory landscape that shaped it, through enrollment, publication, and the policy and litigation that followed.
Background
1975–1991Mar 1975
CDC sets first lead poisoning threshold at 30 µg/dL
Increased Lead Absorption and Lead Poisoning in Young Children" creates a four-class risk system. Chelation recommended for BLLs >=50 µg/dL; iron-lead interaction already recognized. View source ↑
Apr 1978
CDC retains 30 µg/dL threshold in updated prevention guide
Preventing Lead Poisoning in Young Children" keeps the four-class system. About 4% of U.S. children aged 1-5 had BLLs >=30. Iron-calcium deficiency recognized as increasing lead absorption. View source ↑
Jan 4, 1983
Orphan Drug Act creates incentives for rare disease drugs
Congress passes the Orphan Drug Act, granting tax credits, 7-year market exclusivity, and federal grants for drugs treating fewer than 200,000 patients. Succimer will later be approved under this pathway. View source ↑
May 9, 1984
DMSA gets orphan drug designation for pediatric lead poisoning
Bock Pharmaca sponsors the orphan drug application for succimer (DMSA). The designation caps the indicated population at fewer than 200,000 patients, later influencing the 45 µg/dL label restriction. View source ↑
Jan 1985
CDC lowers "elevated" blood lead from 30 to 25 µg/dL
NHANES II data cited: 675,000 children aged 6 months-5 years had BLLs >=30; 12.2% of Black children vs. 2% of white children affected. Iron deficiency recognized as increasing lead absorption. View source ↑
Mar 1987
AAP endorses 25 µg/dL threshold, calls iron deficiency key risk
AAP Committee on Environmental Hazards calls iron deficiency "the single most important predisposing factor" for increased lead absorption. Notes 780,000 U.S. children have BLLs >=30. Published in Pediatrics 1987;79(3):457-465. View source ↑
Dec 1987
CaNa2EDTA chelation doubles brain lead in rats — blood lead drops but brain lead rises
Cory-Slechta et al. show that standard CaNa2EDTA chelation mobilizes lead from bone and kidney but redistributes it to the brain. A single injection doubles brain lead concentration despite lowering blood lead. No net brain lead reduction after a full 5-day course. This finding drives the shift to DMSA for pediatric chelation. View source ↑
Oct 1988
DMSA at 30 mg/kg/day cuts blood lead 78% in 5 days — outperforms CaNa2EDTA
Graziano et al. test three DMSA doses in 21 children with BLL 31-49. The highest dose (1050 mg/m2/day) reduces blood lead by 78% vs. 47% for IV CaNa2EDTA, with no adverse mineral excretion. This dose becomes the basis for the TLC protocol. Blood lead rebounds in all groups after treatment stops. View source ↑
Oct 28, 1988
Lead-Based Paint Poisoning Prevention Act reauthorized
Title IV of the Lead Contamination Control Act reauthorizes the 1971 lead paint law, expanding federal authority over lead paint hazards in housing and establishing HUD's role. View source ↑
May 1989
Only 20% of oral DMSA reaches systemic circulation — 88% biotransformed to disulfide forms
Aposhian et al. give a single DMSA dose to 6 healthy men. Only 20.6% is recovered in urine; 88% of that is in altered disulfide form. DMSA selectively chelates lead, copper, and zinc without affecting iron, calcium, or 27 other elements. These data provide the pharmacokinetic rationale for choosing DMSA over CaNa2EDTA in children. View source ↑
Oct 1989
6 million U.S. children at risk from lead paint; 1.2 million above 15 ug/dL
Mushak and Crocetti summarize an ATSDR report to Congress quantifying the scale of childhood lead exposure. Approximately 6 million children under 7 live in high-risk housing. Blood lead distributions are log-normal, meaning even moderate population means mask large numbers of severely exposed children in the upper tail. View source ↑
Nov 1990 TLC
Chisolm warns chelation is futile without removing lead sources
Chisolm publishes EHP review showing DMSA reduces brain lead in animals, but writes that benefits would be "largely vitiated unless post-treatment exposure to environmental lead is drastically reduced. View source ↑
Jan 1, 1990
EPSDT mandate requires Medicaid to cover children's treatment
Under OBRA 1989, state Medicaid programs must pay for any "medically necessary" service for children, including off-label drugs. This creates a legal obligation to cover chelation if deemed medically necessary. View source ↑
Feb 1990
Meta-analysis: 11 of 12 studies show lead lowers IQ (P < 0.0001)
Needleman and Gatsonis aggregate 12 studies meeting strict inclusion criteria. Joint P-values below 0.0001 for blood lead studies and 0.0005 for tooth lead studies. The effect is robust to removal of any single study. Most individual studies were underpowered, but the combined signal is overwhelming. This meta-analysis becomes a cornerstone for the 1991 CDC guideline revision. View source ↑
Jan 1, 1991
Medicaid Drug Rebate Program forces coverage of FDA-approved drugs
Under OBRA 1990, states must cover any FDA-approved drug if the manufacturer signs a rebate agreement. Combined with EPSDT, this obligates Medicaid to pay for succimer once approved. OBRA 1990 ↑ Veterans’ Benefits Act ↑
Jan 30, 1991
FDA approves succimer (Chemet) for BLLs >=45 µg/dL
McNeil receives marketing approval and 7-year orphan exclusivity through Jan 30, 1998. Clinical trials included children with BLLs as low as 30 µg/dL; the 45 µg/dL cutoff may have been set to keep the population under the 200,000-patient orphan cap. View source ↑
Feb 1991
CDC publishes 20-year plan to eliminate childhood lead poisoning
Strategic Plan estimates 3-4 million children (17%) have BLLs above 15 µg/dL. Calculates $62 billion in societal benefits from abating all pre-1950 housing. Authored by Binder and Falk at CDC. View source ↑
Jun 25, 1991 R&M
Farfel submits R&M study protocol to JHU IRB
Mark Farfel writes to Thomas Hendrix, JHU JCCI chair, describing the planned Lead-Based Paint Abatement and Repair & Maintenance Study in Baltimore. This initiates IRB review for the R&M study. View source ↑
Oct 1991
CDC lowers BLL of concern to 10 µg/dL; recommends universal screening
Preventing Lead Poisoning in Young Children" drops the level of concern from 25 to 10 µg/dL (affecting an estimated 1.7 million children). Chelation threshold lowered from 55 to 45 µg/dL, aligning with succimer's FDA label; clinical discretion allowed for 20-44 µg/dL. View source ↑
Planning & Design
1992–1994May 13, 1992 R&M
Farfel addresses IRB concerns about placing children in partially abated homes
Farfel responds to Hendrix's May 11 letter requesting clarifications about R&M study ethics. Hendrix had raised questions about placing children in partially abated housing. Consent forms attached. View source ↑
Jun 22, 1992 R&M
Battelle formalizes R&M study design with three intervention levels
Battelle Memorial Institute prepares a draft quality assurance plan for the R&M study for EPA, documenting three intervention levels at costs ranging from $1,650 to $7,000. View source ↑
Jul 31, 1992 TLC
NIEHS solicits proposals for a multi-center chelation trial
RFP NIH-ES-92-31 (Clinical Centers) and NIH-ES-92-32 (Coordinating Center) published in NIH Guide Vol. 21 No. 27, seeking sites to test succimer in children with BLLs 20-44 ug/dL. View source ↑
Oct 28, 1992
Title X establishes HUD Office of Lead Hazard Control
Residential Lead-Based Paint Hazard Reduction Act requires lead disclosure in housing sales/rentals and creates federal standards for lead-based paint hazard evaluation and reduction. View source ↑
Nov 23, 1992 TLC
Chisolm proposes KKI as TLC site while running parallel lead study
KKI submits its Technical Plan for TLC to NIEHS with Chisolm as site PI. Chisolm is simultaneously the PI for the R&M study -- creating a dual role at the same institution studying lead in the same Baltimore communities. View source ↑
Dec 9, 1992 TLC
JHU IRB Chair presses Chisolm for answers on TLC design
Thomas Hendrix, Chair of the Johns Hopkins JCCI (IRB), writes to Chisolm requesting clarifications on the proposed TLC protocol before approval. View source ↑
Jan 1993 R&M
R&M study begins enrolling children and collecting baseline data in Baltimore
The KKI R&M study begins enrollment and baseline data collection across 107 houses with 140 children in Baltimore. Data collection runs through November 1994. View source ↑
Jan 25, 1993 TLC
Chisolm replies to IRB questions -- correspondence later scrutinized in court
Chisolm provides written responses to Hendrix's December 9 questions about TLC protocol design, eligibility, and consent. This correspondence becomes part of the IRB review record cited in Grimes litigation. View source ↑
Feb 1993 TLC
NIEHS IRB rejects consent forms -- reading level too high
NIEHS IRB rejects KKI's consent forms because the language exceeds the reading comprehension of the target population (low-income, 40% without high school diplomas). KKI must rewrite and resubmit. View source ↑
Feb 9, 1993 TLC
JHU IRB approves TLC -- later found to have "abdicated its responsibility
The Johns Hopkins JCCI approves TLC protocol on Feb 9-10. Consent forms withheld pending IND number. In 2001, the Maryland Court of Appeals finds this IRB "abdicated its responsibility" and helped researchers "circumvent federal regulations. View source ↑
Mar 1993 TLC
NIEHS and minority health office commit $25M over five years
NIEHS and the Office of Research on Minority Health sign a cooperative agreement providing $5M/year for five years for minority health and environmental research, including TLC. View source ↑
Jun 25, 1993
Rogan appointed TLC Project Officer the same day NIEHS awards KKI the contract
HHS Contracting Officer appoints Walter Rogan as Project Officer for TLC. NIEHS awards Contract No. N01-ES-35362 to KKI. Rogan had chaired the NIEHS IRB (1992-1993) during the exact period TLC proposals were reviewed. View source ↑
Sep 1993 TLC
Five TLC contracts signed: Baltimore, Philly, Newark, Cincinnati
EHP publishes "Succimer Gets TLC" announcing signed contracts with four clinical centers (KKI, St. Christopher's, UMDNJ, Cincinnati Children's) and one coordinating center. View source ↑
Mar 1994 R&M
R&M study 12-month follow-up begins -- partial abatement data starts coming in
Follow-up data collection begins for the R&M study, running through May 1995. Results will show that low-cost interventions ($1,650) are less effective at reducing lead dust than higher-cost ones ($7,000). View source ↑
Apr 1994
No safe threshold: IQ declines by 2.6 points per 10 ug/dL, steeper at lower levels
Schwartz pools 7 studies using inverse-variance weighting and finds a 2.57-point IQ loss from 10 to 20 ug/dL. Studies with lower mean BLL have steeper slopes, suggesting a logarithmic dose-response. Nonparametric smoothing of the Boston cohort shows no threshold down to 1 ug/dL. This paper provides the epidemiologic foundation for TLC's IQ endpoint. View source ↑
Enrollment & Treatment
1994–1997Aug 10, 1994 TLC
First child walks into a TLC screening clinic
The first TLC screening clinic visit occurs, launching the enrollment pipeline. Of 1,854 children ultimately screened at first visit, ~45% will fail to qualify due to BLL regression to the mean. View source ↑
Aug 23, 1994 TLC
Protocol Version 9 locks in the 26-day off-label dosing regimen
Protocol V9 establishes the 26-day succimer course (7 days beyond FDA-approved 19 days), body-surface-area dosing (higher doses in smaller children), and suspension of vitamins during chelation. View source ↑
Sep 7, 1994 TLC
Enrollment opens at all four sites
Children aged 12-33 months with BLLs 20-44 ug/dL begin enrolling at Baltimore, Philadelphia, Newark, and Cincinnati. Each site operates under the same protocol in vastly different housing and demographic contexts. View source ↑
Oct 1994 TLC
Homes HEPA-vacuumed and mopped once -- the entire environmental fix
Pre-randomization professional cleanings begin: HEPA vacuuming, trisodium phosphate mopping, minor paint stabilization. Lead in paint assumed, not measured. 765 of 780 homes cleaned. This single visit is the full environmental intervention. View source ↑
1995
AAP publishes treatment guidelines for lead exposure in children
AAP issues clinical guidance on managing lead-exposed children, reflecting evolving practice in the early enrollment phase of TLC. View source ↑
Jan 1995
Decision model projects chelation prevents 22.5% of reading disability — but 'no definitive data' exist
Glotzer et al. model chelation cost-effectiveness assuming a 70% reduction in reading disability risk. EDTA chelation costs $1,778/child but saves $900M/year when remedial education costs are included. The authors explicitly note 'no definitive data exist regarding the effect of chelation with respect to lead-induced neurotoxicity.' Succimer is excluded from the model as too new. The TLC trial is designed to fill this gap. View source ↑
Jul 21, 1995 R&M
Farfel's R&M report shows cleaning reduces dust but not enough to meet standards
The 12-month preliminary report shows all three R&M intervention levels reduce dust lead, but only children starting above 20 ug/dL see statistically significant BLL drops. The lowest-cost intervention is least effective. View source ↑
Dec 20, 1996 TLC
Last screening visit -- enrollment pipeline closes after 28 months
The final screening clinic visit occurs, ending the intake period. Over 28 months, 1,854 children screened at first visit yielded 1,009 at second visit and ultimately 780 randomized. View source ↑
1997
CDC updates screening guidance for young children
Screening Young Children for Lead Poisoning" updates the 1991 universal screening recommendation with targeted approaches based on local prevalence data. Published during the TLC enrollment period. View source ↑
Jan 22, 1997 TLC
780 children randomized: 396 succimer, 384 placebo
The last child is randomized, completing enrollment. Population: 77% African-American, 72% single-parent, >80% on Medicaid, mean parental IQ 79-81, baseline MDI 82-84 (>1 SD below normed mean). View source ↑
Mar 1997 TLC
75% of succimer children need a second course -- BLLs rebounding
After the first 26-day chelation course, three-quarters of succimer-group children fail to stay below 15 ug/dL. BLL rebound begins within one week of treatment cessation. 81% of those retreated need a third course. View source ↑
Follow-Up
1997–1998Apr 4, 1997 TLC
Contaminated vitamins begin shipping to all four sites
TLC pharmacy starts distributing repackaged supplements from lot #23198. The iron-wax particles contain 250-600 ppm lead, producing ~32-36 ug lead per tablet. 984 bottles shipped across all sites. View source ↑
Jun 1997 TLC
Last treatment courses completed -- 99% done by 9 months
Final succimer/placebo courses wrap up. All children with baseline BLLs 35-44 ug/dL who completed treatment required all three courses. 40% of succimer families reported difficulty administering the drug. View source ↑
Jul 3, 1997 TLC
Raw-material supplier reveals lead in the iron-wax particles
Particle Dynamics informs NutroPharmaceuticals that the iron-wax particles used in TLC vitamin supplements are contaminated with lead. Three months of shipments have already gone out. View source ↑
Jul 7, 1997 TLC
TLC pharmacy notified -- contaminated vitamin distribution halted
NutroPharmaceuticals notifies the TLC pharmacy. Distribution from the affected lot is immediately stopped across all four clinical sites. View source ↑
Jul 8, 1997 TLC
Formal recall launched -- DSMC, FDA, and all IRBs notified
Recall initiated. The Data and Safety Monitoring Committee, FDA, and all site IRBs are notified. FDA classifies the event as unlikely to cause irreversible harm; authorizes voluntary recall only. View source ↑
Jul 9-10, 1997 TLC
Letters mailed to 628 exposed families; phone calls begin
Recall letters mailed Jul 9-10. Phone contact starts simultaneously. 628 of 780 children (80.5%) identified as potentially exposed. One site had encouraged families to give supplements to siblings. View source ↑
Jul 28, 1997 TLC
IRBs approve sibling blood draws; NJ lab finds 32 ug lead/tablet
NIEHS and CDC IRBs approve blood testing of siblings who shared the supplements. A New Jersey laboratory confirms 32 ug lead per tablet. 149 siblings are eventually tested. View source ↑
Aug 1997 TLC
First enrollees reach 36-month mark -- IQ testing begins
Children randomized in August 1994 reach the primary endpoint window. WPPSI-R Full-Scale IQ assessments begin. The trial was powered at 0.82 to detect a 3-point difference. View source ↑
Sep 15, 1997 TLC
NTP confirms 36 ug lead per tablet -- independent lab agrees
National Toxicology Program contractor (Battelle) reports 36 +/- 2 ug lead per tablet, consistent with the NJ lab's 32 ug finding. The trial's own vitamin supplement contained lead at levels that could measurably affect BLLs. View source ↑
Oct 13, 1997 TLC
Recall completed: 96% of exposed families contacted
Three-month recall effort ends. 601 of 628 families (96%) reached. Trial data frozen for DSMC review. Mean BPb increase among 571 tested children: 1.2 +/- 0.2 ug/dL, but no individual-level trajectory analysis performed. View source ↑
Nov 1997 TLC
Protocol Version 10 issued mid-trial
Protocol V10 replaces V9. Specific changes between versions -- including any modifications to the outcome battery or assessment schedule -- occurred during active data collection. Transcribed PDF ↑ Archived HTML
Dec 1997 TLC
DSMC reviews contamination data; Needleman among members
The Data and Safety Monitoring Committee reviews the frozen dataset and contamination incident. H.L. Needleman serves on the committee. The committee's specific findings and recommendations remain unpublished. View source ↑
Results
1998–2001Jan 30, 1998
McNeil's orphan drug exclusivity for succimer expires
The 7-year orphan market exclusivity period ends. Generic competition becomes possible, though Chemet remains the standard branded product. View source ↑
Jul 1998 TLC
TLC design paper reveals population under extreme stress: parental IQ 80, 97% on public assistance
The TLC Group describes the trial's architecture: 780 children randomized across 4 cities, extended 26-day succimer courses, home cleaning, vitamin supplements. Baseline developmental scores already 1 SD below norms (MDI 82). Population is 77% Black, 72% single-parent, 97% on public assistance. Iron-deficient children were treated pre-enrollment, but ferritin data for the randomized cohort go unreported. View source ↑
Mar 1999 R&M
CLEARS trial: intensive biweekly cleaning cuts BLL 34% — single TLC cleaning insufficient
Rhoads et al. randomize 113 children in Jersey City to biweekly household cleaning vs. controls. Homes cleaned 20+ times show a 34% BLL reduction (-3.9 ug/dL). Education alone has no effect. The dose-response relationship (more cleanings = lower BLL) implies the TLC trial's single baseline cleaning was inadequate to control ongoing exposure. View source ↑
Mar 1, 1999 R&M
R&M study families sue KKI for using children as "measuring tools
Erica Grimes and Myron Higgins file suit against KKI in Baltimore City Circuit Court (24-C-99-000925). They allege KKI recruited children into partially abated housing to measure lead absorption, and that consent forms failed to disclose the risk. View source ↑
Jul 1999 TLC
TLC screening cohort: 'no iron deficiency' — but ferritin threshold set at <10, below all modern standards
Serwint et al. compare 787 TLC screening children to 222 NHANES III controls. Iron depletion rates appear similar (11% vs. 13%), but the threshold is <10 ug/L — below WHO (<12), clinical (<15), and neurodevelopmental (<20-25) standards. MCV is significantly lower and RDW significantly higher in TLC children, suggesting subclinical iron compromise the ferritin threshold misses. Only arithmetic means reported for a right-skewed distribution. View source ↑
Aug 1999 TLC
TLC's own vitamins were contaminated with lead: ~36 ug per tablet, 628 children exposed
Rogan et al. report that iron-wax particles in the trial's vitamin supplements contained 250-600 ppm lead, producing ~36 ug lead per tablet. 628 children were potentially exposed from April to July 1997. Investigators report a mean 1.2 ug/dL BLL increase with no dose-response, concluding the contamination was inconsequential. The irony: the trial designed to address lead poisoning inadvertently gave children an additional lead source through the iron supplement. View source ↑
2000 R&M
Farfel and Chisolm publish R&M extension -- their own data shows cleaning alone failed
Extended R&M study results show that homes receiving only minor repairs and professional cleaning were more likely to re-accumulate high lead dust levels within two years. Professional cleaning was inadequate to meet EPA clearance standards. View source ↑
Feb 2000 TLC
Last child reaches 36 months -- primary endpoint collection ends
Children randomized in January 1997 complete WPPSI-R assessment. 745 of 780 children (96%) retained. Mean Full-Scale IQ: 80.6 in both groups -- no difference. View source ↑
Sep 12, 2000 R&M
Grimes appeal filed after Circuit Court sides with KKI
After the Circuit Court grants summary judgment to KKI, plaintiffs appeal to the Court of Special Appeals (Sept. Term 2000, No. 128). The case is eventually certified to the Court of Appeals. View source ↑
Nov 2000 TLC
Safety paper: succimer cuts BLL by 4.5 ug/dL for 6 months but 83% need retreatment; unexplained trauma excess
The TLC Group reports succimer lowered BLL by 4.5 ug/dL over 6 months (peak difference ~11 ug/dL at 1 week, then immediate rebound). 83% of succimer children required a second course; 83% of those required a third. Physical evidence of trauma was found in 14.9% of succimer vs. 9.9% of placebo children; 5 succimer and 0 placebo children were hospitalized for trauma. The authors acknowledged 'TLC is too small a trial to establish safety. View source ↑
Apr 2001
Blood lead predicts only 4 of 19 cognitive tests; cumulative bone-derived dose predicts 14 of 19
Links et al. apply linear systems theory to 535 former lead workers, comparing four dose metrics. Cumulative tibial lead (AUC') predicts 14 of 19 cognitive tests cross-sectionally, versus only 4 for current blood lead. Blood lead has a 30-day half-life vs. 27 years for bone lead. The TLC trial relied entirely on blood lead as both the treatment target and outcome metric — a fundamentally inadequate surrogate for brain dose. View source ↑
May 10, 2001 TLC
NEJM: Succimer lowers blood lead but produces no cognitive benefit at 36 months
The landmark TLC result. 780 children randomized, 96% retention. Succimer lowered BLL by 4.5 ug/dL over 6 months but the adjusted IQ difference was -1.1 points (succimer lower, not significant). No improvement on any of 15 cognitive, behavioral, or neuropsychological measures. Succimer children grew 0.35 cm less. The authors conclude chelation is 'not indicated' below 45 ug/dL. This paper becomes the evidence base for removing chelation from guidelines. View source ↑
Aug 2001 TLC
7-year follow-up begins with expanded neuropsych battery
School-age assessments start for earliest enrollees. Battery now includes WISC-III, NEPSY, Conners CPT, CVLT-C, Woodcock reading, BASC parent and teacher ratings, and neurological exam. View source ↑
Aug 9, 2001 R&M
Martin v. KKI filed -- another R&M family sues
Lovette Martin III files suit against KKI and others in Baltimore City Circuit Court (24-C-01-003868). View source ↑
Aug 16, 2001 R&M
Maryland's highest court compares KKI study to Nuremberg violations
The Maryland Court of Appeals issues its landmark opinion in Grimes v. KKI (366 Md. 29). The court compares the R&M study to the Nuremberg experiments, finds KKI used children's blood as a "measuring tool," and holds that parental consent cannot authorize placing healthy children in known hazardous environments. Vacates summary judgment for KKI. View source ↑
Sep 5, 2001 R&M
Post-Grimes wave: Chase and Coles families file against KKI
Within weeks of the Grimes opinion, Jasmine Chase (24-C-01-004338) and Quyaisha Coles (24-C-01-004337) file separate suits against KKI in Baltimore City Circuit Court. View source ↑
Sep 13, 2001 R&M
Bogan v. KKI filed in the Grimes aftermath
Brandon Bogan files suit against KKI (24-C-01-004465) in Baltimore City Circuit Court, part of the wave of R&M suits triggered by the Grimes opinion. View source ↑
Aftermath
2002–20212002 R&M
KKI General Counsel publishes defense of R&M study in law journal
Joanne Pollak, KKI Vice President and General Counsel, publishes a legal-academic defense arguing the Grimes court had an incomplete record and that the R&M study actually reduced lead exposure. View source ↑
Mar 2002 TLC
First post-TLC guideline recommends against chelation below 45
ACCLPP's "Managing Elevated Blood Lead Levels Among Young Children" cites TLC as the principal reason not to chelate for BLLs 20-44 µg/dL. TLC PI Walter Rogan served as ex officio ACCLPP member; David Bellinger authored the developmental chapter. View source ↑
Jul 2002
Needleman: 'How little can we spend?' — the retreat from primary prevention that made TLC necessary
Writing in response to the Kennedy-Krieger case, Needleman argues that the abandonment of comprehensive lead abatement ($34B estimated cost vs. $62B in benefits) created the conditions requiring cheap-alternative studies like TLC. The question shifted from eliminating lead in housing to whether pharmacologically lowering blood lead could reverse damage already done. View source ↑
Oct 2002 TLC
Paradox: naturally falling BLL predicts IQ gains in placebo group — drug-induced BLL drops do not
Liu et al. reanalyze TLC data by BLL change rather than treatment assignment. At 36 months, placebo children gain 4.0 IQ points per 10 ug/dL of natural BLL decline. Succimer children show no such association at any time point. This implies either chelation removes lead from a different compartment than what matters for the brain, or that families who reduced environmental exposure also provided more cognitive stimulation. View source ↑
Nov 4, 2002 TLC
First TLC-specific lawsuit filed -- Deshields calls the study "misleadingly entitled
Shawnta Deshields files the first TLC-specific federal lawsuit (02-CV-3694) against KKI, alleging children were "negligently enrolled and enticed into living in lead infested houses for the purpose of perpetuating research." KKI concedes the purpose was measurement, not treatment. View source ↑
Dec 2002 TLC
After professional cleaning, 69% of TLC homes still failed EPA lead dust standards
Ettinger et al. report that 765 of 780 TLC homes were professionally cleaned. Floor dust lead dropped 32%, windowsills 66%. But 69% of homes above EPA clearance standards before cleaning remained above after cleaning. Effectiveness varied dramatically by site: Baltimore 54% floor reduction vs. Philadelphia 9%. Lead in paint was never measured — it was simply assumed present. TLC children continued facing significant ongoing exposure throughout the trial. View source ↑
Dec 16, 2002 R&M
Higgins v. KKI dismissed by stipulation
The companion Grimes case (Myron Higgins, 24-C-95-066067) is dismissed by stipulation after the Court of Appeals remanded. View source ↑
Apr 17, 2003
NEJM: IQ drops 7.4 points in the first 10 ug/dL — proportionally greater harm at lower levels
Canfield et al. follow 172 Rochester children with serial blood lead and IQ measures. A semiparametric model shows 7.4-point IQ decline from 1 to 10 ug/dL, but only ~2.5 additional points from 10 to 30. The nonlinear dose-response means TLC children (mean BLL 26) were on the flat part of the curve, making treatment effects harder to detect. Published in the same NEJM issue as Rogan and Ware's editorial on TLC implications. View source ↑
Apr 17, 2003 TLC
Rogan & Ware editorial: 'Prevention is the only plausible strategy' — chelation effects are irreversible
In an NEJM Perspective accompanying Canfield's paper, the TLC PI and biostatistician explicitly state that TLC chelation 'had no beneficial effects on tests of cognition, behavior, or neuropsychological function.' They note that lead damage appears long-lasting and irreversible, and that there is no safety margin at existing exposure levels. This is the trial leadership's own public concession. View source ↑
Apr 2, 2003 TLC
Federal judge orders KKI to open its TLC files -- six banker's boxes produced
In Deshields, the court orders KKI to produce all TLC study documents. KKI delivers approximately six banker's boxes. The judge states: "all of the documents ought to be rounded up, collected, there should be a repository. View source ↑
May 12, 2003 R&M
Grimes v. KKI finally dismissed by stipulation
The original Grimes case (24-C-99-000925) is dismissed by stipulation, four years after filing and nearly two years after the landmark Court of Appeals opinion. View source ↑
Jan 2004 TLC
7-year follow-up ends: 647 children assessed, 128 lost
Final school-age assessments completed. 647 of 780 children evaluated (83%). 68 succimer vs. 43 placebo children had discontinued treatment -- differential dropout never formally analyzed for bias. View source ↑
Feb 2004 TLC
Succimer-treated children grew 0.43 cm less — and this is the only TLC paper to report baseline ferritin
Peterson et al. find succimer-treated children grew significantly less in height: -0.27 cm at 9 months, -0.43 cm at 34 months. The deficit emerged during treatment and persisted. Buried in Table 1 as a covariate are the only published baseline ferritin values for the randomized cohort: 28.5 and 28.1 ug/L, with SDs nearly equal to the means, confirming a heavily right-skewed distribution. No analysis of ferritin as an effect modifier was ever performed. View source ↑
Jul 2004 TLC
Age 7: still no cognitive benefit; attention/executive function significantly worse in succimer group
Dietrich et al. assess 647 TLC children at school entry on an expanded battery (WISC-III, NEPSY, Woodcock, BASC). No benefit on any measure. One statistically significant finding favors placebo: NEPSY Attention/Executive Functions (P = .045). Succimer children are now 1.17 cm shorter. A quarter of all children still have BLL above 10 at age 7. Concurrent BLL is significantly associated with lower IQ (beta = -0.42 per ug/dL, P < .001). View source ↑
Jul 30, 2004 TLC
Deshields v. KKI quietly dismissed -- probable settlement with broad release
Deshields is dismissed with prejudice by stipulation. The release covers "all claims that were brought or could have been brought against the Kennedy Krieger Institute, Inc., and/or any of its agents, servants, or employees. View source ↑
Oct 2004 TLC
Rogan tells ACCLPP findings "do not support another trial
Walter Rogan presents TLC results to ACCLPP, calls succimer "an expensive drug" that "resulted in symptoms in children who were previously asymptomatic." Mary Jean Brown reports Medicaid programs are dropping succimer coverage below 45 µg/dL. View source ↑
Oct 2004 TLC
ACCLPP shifts policy from treatment to housing-based prevention
Preventing Lead Exposure in Young Children: A Housing-Based Approach" recommends primary prevention through housing interventions rather than screening and treating poisoned children. Published under CDC Director Julie Gerberding. View source ↑
2005 TLC
ACCLPP updates flagship prevention statement with post-TLC evidence
Updated "Preventing Lead Poisoning in Young Children" emphasizes primary prevention over treatment, incorporating TLC trial results. Part of the 2004-2005 guideline series shifting policy away from chelation. View source ↑
2005 TLC
ACCLPP publishes implementation guide for primary prevention
Building Blocks for Primary Prevention" provides practical strategies for state and local agencies to abate lead-based paint hazards. Continues the post-TLC shift toward prevention rather than treatment. View source ↑
Mar 8, 2005 R&M
Woods v. Baltimore 132 Partnership filed
Eric Woods files suit (24-C-05-002696) in Baltimore City Circuit Court against landlords and partnerships. View source ↑
May 2005 TLC
Concurrent BLL at age 7 drives IQ (-5.4 points per 10 ug/dL) — peak BLL at age 2 does not
Chen et al. reanalyze TLC data and find concurrent BLL at age 7 is the strongest predictor of IQ (-5.4 points per 10 ug/dL), while baseline BLL at age 2 is not significant (-1.1 points, P = NS). When both are in the model, only concurrent BLL matters. This implies TLC's transient chelation (effective ~10 months) could not improve IQ at ages 5-7 when blood lead had re-equilibrated and ongoing exposure continued. View source ↑
Oct 2005 TLC
AAP adopts TLC-based recommendation against chelation below 45
Lead Exposure in Children: Prevention, Detection, and Management" (Pediatrics 2005;116(4):1036-1046) cites TLC. Walter Rogan, TLC PI and NIEHS Liaison to the AAP Committee on Environmental Health, was primary author. View source ↑
Dec 15, 2005 TLC
First TLC participant sues landlord directly -- Sumpter v. City Homes
Dylan Sumpter, a TLC participant, files suit against City Homes in Baltimore City Circuit Court, targeting the landlord rather than KKI. View source ↑
2006 TLC
USPSTF issues first "insufficient evidence" statement on lead screening
First USPSTF review of childhood lead screening finds insufficient evidence to recommend for or against routine screening of asymptomatic children. Updated in 2019 with TLC as centerpiece evidence. View source ↑
Apr 2006 TLC
Succimer group has higher systolic blood pressure 1-5 years after treatment — possible calcium depletion
Chen et al. find succimer-treated children have systolic BP 1.09 mmHg higher than placebo from 12-60 months follow-up (P < 0.05). Despite succimer lowering BLL for 9-10 months, no blood pressure benefit occurred. The authors speculate the BP increase may result from calcium excretion during chelation. Another potential adverse effect of a treatment that produced no cognitive benefit. View source ↑
2007 TLC
ACCLPP addresses BLLs below 10 µg/dL but adds no treatments
Interpreting and Managing Blood Lead Levels Below 10 µg/dL" acknowledges harm at levels below the 1991 threshold but provides no new pharmacological interventions. Environmental and educational measures only. View source ↑
Feb 2007
Animal evidence: succimer reverses some lead-induced cognitive deficits — but causes lasting harm without lead exposure
Stangle et al. test succimer in a 3x2 factorial design with 120 rats. Lead-exposed rats given succimer show significant improvement in learning and arousal regulation — the first evidence any chelator can reverse lead's cognitive effects. But succimer given to non-lead-exposed rats produces lasting cognitive impairment comparable to high lead exposure. The authors note TLC achieved only a 4.5 ug/dL BLL difference — far less than the animal protocol that showed benefit. View source ↑
Mar 2007 TLC
Lead directly damages behavior independent of IQ — concurrent BLL at age 7 drives externalizing problems
Chen et al. use path analysis on TLC data to separate direct vs. IQ-mediated effects of lead on behavior. At age 7, concurrent BLL has significant direct effects on teacher-rated externalizing problems, school problems, and behavioral symptoms that are not mediated through IQ. Blood lead at age 2 has no significant effect on age-7 behavior. 39% of TLC children have teacher-rated school problems in the at-risk or clinical range. View source ↑
Mar 22, 2007 TLC
Most detailed TLC complaint filed -- Featherstone alleges KKI recruited landlords to rent to families with young children
Shayonna Featherstone files against KKI (24-C-07-002027). The complaint alleges KKI recruited landlords and offered financial inducements to keep children in the study. Eight counts filed; each plaintiff seeks $2,000,000. The compiled removal document (726 pages) contains the NIEHS contract, sworn affidavits, and the full complaint. View source ↑
May 2007 TLC
Only positive TLC finding: succimer improves postural balance and gait in 161 Cincinnati children
Bhattacharya et al. assess 161 Cincinnati TLC children on force platform and gait walkway at age 5+. Succimer group shows significantly less postural sway during dynamic bending (6.6%, P = 0.04), 19% less medio-lateral sway during obstacle crossing (P = 0.001), and lower gait forces during normal walking. This is the only TLC publication showing significant benefit from succimer on any neuromotor measure. Authors caution the findings do not support changing clinical practice. View source ↑
May 4, 2007 TLC
KKI removes Featherstone to federal court, claims NIEHS controlled every facet of TLC
KKI files Notice of Removal, asserting federal jurisdiction because NIEHS "specifically directed each and every facet" of TLC. Sworn affidavits from KKI Project Manager Brophy and co-investigator Davoli state the federal government "retained and exercised a very detailed level of control over every aspect of this study. View source ↑
Jun 4, 2007 TLC
Rogan files safety monitoring defense in Featherstone case
TLC principal investigator Walter Rogan files a court document describing TLC safety monitoring procedures, arguing the trial met its ethical obligations to participants. Case 1:07-cv-01120-WMN. View source ↑
Nov 6, 2007 TLC
Federal court sends Featherstone back to state court -- calls TLC "non-therapeutic
U.S. District Court (Judge William M. Nickerson) remands Featherstone to state court. The court rejects KKI's federal control argument, finding NIEHS oversight was to "ensure relative uniformity" of the multi-center trial, not to further federal policy. Footnote 3 classifies TLC as "non-therapeutic" because succimer "conferred no known, long-term benefit. View source ↑
May 30, 2008 R&M
McNair v. Hugo Moser Research Institute filed
Lisa Edwards McNair files suit against the Hugo W. Moser Research Institute at KKI (24-C-08-003381) in Baltimore City Circuit Court. View source ↑
Aug 2009
Age 6 BLL predicts IQ 7 points better than age 2 — TLC may have targeted the wrong developmental window
Hornung, Lanphear, and Dietrich combine Cincinnati and Rochester cohorts (n=397). Using a novel ratio approach to avoid collinearity, they show BLL at ages 5-6 is far more strongly associated with IQ than early childhood BLL. Children whose 6-year BLL was 50% higher than their 2-year BLL lost 7.0 IQ points. Criminal arrest rates were 3.35x higher. TLC's chelation at ages 1-3 may have targeted the wrong window entirely. View source ↑
Jan 6, 2010 TLC
Featherstone settled -- KKI and Davoli voluntarily dismissed
KKI and Cecilia Davoli are voluntarily dismissed from Featherstone. Settlement with costs paid finalized April 20, 2010. View source ↑
Jul 13, 2011 TLC
White v. KKI filed -- becomes the controlling TLC precedent
Tyron White files against KKI (24-C-11-004729). The case reveals that KKI's professional cleaning actually increased lead dust in four of seven areas. White's BLL data, withheld from his mother during the study due to double-blinding, was only produced through discovery. View source ↑
Sep 14, 2011 R&M
Hill v. Smith filed
Diamond Hill files suit (24-C-11-005883) in Baltimore City Circuit Court. View source ↑
Dec 29, 2011 R&M
Wyatt v. Kane filed
Iesha Wyatt files suit (24-C-11-008976) in Baltimore City Circuit Court. View source ↑
2012 TLC
Wave of TLC lawsuits filed naming KKI, JHU, IRB members, and individual researchers
Multiple TLC families file suit in a single wave. The Ervin complaint names KKI, Johns Hopkins University, JHU Hospital, the Bloomberg School, the JHU School of Medicine IRB, Cecilia Davoli, Lewis Becker, David Cornblath, Paul Leitman, Hayden Braine, Mark Farfel, and Thomas Hendrix as defendants. View source ↑
Jan 4, 2012 TLC
ACCLPP replaces "level of concern" with reference value of 5 µg/dL
ACCLPP recommends replacing the 10 µg/dL "level of concern" with a reference value based on the 97.5th percentile of NHANES data (initially 5 µg/dL). The 45 µg/dL chelation threshold is unchanged, widening the treatment gap. No new treatments recommended. View source ↑
Feb 8, 2012 TLC
Thomas v. KKI filed -- TLC participant
Deishaun Thomas files against KKI (24-C-12-000802). Case proceeds to the Court of Special Appeals, which issues an unreported opinion on March 25, 2015. View source ↑
Feb 16, 2012 TLC
Jones v. KKI filed -- reveals KKI confirmed hazards but did not remediate
Jeffrey Jones files against KKI (24-C-12-001069). Discovery reveals KKI confirmed flaking paint and rising dust lead levels at Jones's home but performed no additional cleaning. Jones's BLL peaked at 33 ug/dL during the study. Trial judge states: "if that were the case then I think they violated their standard of care under Grimes. View source ↑
Apr 3, 2012 TLC
Ervin v. KKI filed as class action -- jury later finds KKI breached its duty
James Ervin files against KKI, JHU, the Bloomberg School, the IRB, and six individual researchers (24-C-12-002081). Originally filed as a class action. At trial, the jury finds KKI breached its duty to Ervin but that the breach did not cause his injuries. Expert testimony establishes the succimer rebound effect. View source ↑
Sep 10, 2012 R&M
Sabb v. Uptown Realty filed
Jaquitta Sabb files suit (24-C-12-005322) in Baltimore City Circuit Court against landlords. View source ↑
Sep 20, 2012 R&M
Long v. KKI filed
Deandre Long files against KKI (24-C-12-005534) in Baltimore City Circuit Court. View source ↑
Mar 1, 2013 TLC
KKI moves to bar any mention of Grimes at White trial
In White v. KKI, KKI files "Motion in Limine to Preclude Any Mention During Trial of the Maryland Court of Appeals Decision in Grimes v. Kennedy Krieger Institute, Inc." (Motion 126). View source ↑
Jul 30, 2013 R&M
Miller v. KKI filed
Caprice Miller files against KKI (24-C-13-004865) in Baltimore City Circuit Court. View source ↑
Sep 2014 TLC
TLC cohort mean IQ 86.7 at age 7; low mercury levels rule out confounding neurotoxicant
Wang et al. measure methylmercury in 613 TLC children at age 7 and find very low levels (geometric mean 0.56 ug/L). Higher mercury is paradoxically associated with higher IQ (+2.1 points per ug/L), likely reflecting fish consumption benefits. Mercury is excluded as a confounding neurotoxicant. The persistent mean IQ of 86.7 — 13 points below the population norm — confirms lasting cognitive harm from lead exposure despite chelation. View source ↑
Feb 13, 2015 TLC
TLC participant wins $2.69M jury verdict -- sued the landlord, not KKI
Brionna Heckstall, a TLC participant, wins a $2,692,250 jury verdict (reduced to $1,959,250 after the non-economic damages cap) against her landlords in Baltimore City Circuit Court (24-C-15-000776). TLC study records are central evidence. KKI assessor had rated both of her homes at cleanup level "5" -- the highest. Expert testimony establishes she lost eight IQ points. Her lawyer calls her KKI's "lab rat. View source ↑
Mar 25, 2015 TLC
Thomas v. KKI -- Court of Special Appeals issues unreported opinion
The COSA issues an unreported opinion in Thomas v. KKI (No. 2249, Sept. Term 2013), following the White precedent. View source ↑
Mar 26, 2015 R&M
Carpenter v. KKI filed
Charnice Carpenter files against KKI (24-C-15-001529) in Baltimore City Circuit Court. View source ↑
Apr 10, 2015 TLC
White v. KKI appellate opinion -- court classifies TLC as "therapeutic
The Court of Special Appeals affirms the jury verdict for KKI in White. The court holds "as a matter of law" that TLC was therapeutic, directly contradicting the federal court's 2007 non-therapeutic classification. However, the opinion notes the placebo arm was "arguably nontherapeutic" (p. 25, n. 10) and reveals KKI's cleaning actually increased lead dust in four of seven areas tested. View source ↑
Apr 21, 2015 TLC
Jones v. KKI affirmed -- jury found no negligence
The COSA affirms the jury's finding of no negligence in Jones v. KKI. The court notes KKI's own post-study articles concluded that professional cleaning was inadequate to meet EPA standards. View source ↑
Jul 2016 TLC
AAP reaffirms no chelation below 45, endorses 5 µg/dL reference
Prevention of Childhood Lead Toxicity" (Pediatrics 2016;138(1):e20161493) continues to cite TLC against chelation below 45 µg/dL. No pharmacological intervention recommended between 5 and 44 µg/dL. View source ↑
Aug 23, 2016 R&M
Abrams v. KKI filed -- latest individual R&M case
Brandon Abrams files suit against KKI (24-C-16-004712) in Baltimore City Circuit Court. The last documented individual R&M case filing. View source ↑
Jun 22, 2018 TLC
Ervin v. KKI affirmed -- jury found breach but no causation
The COSA affirms the jury verdict in Ervin (No. 2401, Sept. Term 2016). The jury had found KKI breached its duty but that the breach did not cause Ervin's injuries. Expert testimony established that succimer causes rebound -- "lead in blood's only a small amount of lead in the body, and succimer is mostly taking it out of the blood. So if you took all of it out of the blood, it's still going to rebound back up. View source ↑
Jan 15, 2019 TLC
Heckstall verdict affirmed -- TLC records validated as courtroom evidence
The COSA affirms Heckstall's $1,959,250 verdict. Cert. denied April 2, 2019. The opinion establishes that TLC study records -- cleanup levels, BLL data, home assessments -- are admissible and probative evidence of lead exposure and injury. View source ↑
Apr 16, 2019 TLC
USPSTF cites TLC as only good-quality RCT; issues "I" statement
Cantor et al. publish the evidence review in JAMA (2019;321(15):1510-1526), identifying TLC as the sole good-quality RCT of chelation. Finds "insufficient evidence" for screening and treatment, effectively discouraging identification of lead-exposed children. View source ↑
Dec 10, 2019 R&M
Last R&M case reaches Maryland appellate courts -- twenty years after Grimes
KKI v. Partlow (24-C-09-008243), the final R&M case, reaches the Appellate Court of Maryland. Twenty years after Grimes was filed, litigation over the R&M study is still being resolved. View source ↑
2021 TLC
CDC lowers blood lead reference value to 3.5 µg/dL
Updated from 5 µg/dL based on NHANES 97.5th percentile data. Chelation threshold remains 45 µg/dL, creating a 12.9-fold treatment gap. Between 3.5 and 44 µg/dL, no pharmacological intervention is recommended. View source ↑